Conversion Therapy to Everolimus in Renal Transplant Recipients: Results After One Year
Background Two new diagnoses have been causing graft loss during long-term followup, namely, chronic nephropathy and anticalcineurinic toxicity. The advent of the mammalian target of rapamycin (m-TOR) obviates anticalcineurine toxicity and reduces posttransplant malignancy incidence with good inmunosuppressive potential. We examinated the renal and metabolic behavior in renal transplant recipients who required conversion from an […]
Conversion Therapy to Everolimus in Renal Transplant Recipients: Results After One Year Read More »